Active ingredientTrilaciclibCat. No. P-T209-001CAS 1374743-00-6Family · Pharmaceutical analytical standards
Trilaciclib
A CDK4/6 kinase inhibitor given intravenously before chemotherapy, approved in the United States in 2021 to reduce bone marrow suppression in adults with extensive-stage small cell lung cancer. This family brings together the active ingredient and other impurities.
Did you know?The FDA considered it first in its class: while the other CDK4/6 inhibitors slow down cancer cells, trilaciclib pauses the healthy cells of the bone marrow to protect them from chemotherapy.
Go to the active ingredient →Active ingredientTrilaciclibCat. No. P-T209-001CAS 1374743-00-6
ImpurityN-Desmethyl TrilaciclibCat. No. P-T209-002CAS 1374743-01-7No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.